Structure Therapeutics presents promising data on novel obesity and Parkinson's disease treatments at scientific conference

From GlobeNewswire: 2025-06-20 19:30:00

Structure Therapeutics Inc. (NASDAQ: GPCR) will present two late-breaking posters at the American Diabetes Association 85th Scientific Sessions in Chicago. The company’s novel oral small molecule, ACCG-2671, shows promise as a dual amylin and calcitonin receptor agonist for obesity therapy. Preclinical data demonstrates significant weight loss effects, especially when combined with a GLP-1 receptor agonist. Another poster will highlight the neuroprotective effects of a small molecule GLP-1 receptor agonist in a Parkinson’s disease-like model. Both presentations are scheduled for Sunday, June 22, at 12:30 p.m. CT. Structure Therapeutics focuses on developing oral small molecule treatments for metabolic and cardiopulmonary conditions with unmet medical needs.



Read more at GlobeNewswire: Structure Therapeutics Announces Two Late-Breaking Poster